Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension
European Respiratory Journal · 2025-06 · 65 (6) · 2500064
DOI: 10.1183/13993003.00064-2025 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Respiratory Journal, online erschienen am 23.04.2025. Verfasst von Karen M Olsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Extract Triple combination therapy including prostacyclin pathway agents is considered standard of care for patients with advanced pulmonary arterial hypertension (PAH) [1]. However, treatment with prostacyclin pathway agents, especially with parenteral prostacyclin analogues, is associated with considerable side effects, treatment burden, risks, and high costs. In patients’ view, the initiation of parenteral prostacyclin analogues has a major impact on their daily life [2].
Autor:innen und Institutionen
- Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany.
- These authors contributed equally.
- Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany hoeper.marius@mh-hannover.de.
ORCID-Profile: Jan Fuge, Jan C Kamp, Marius M Hoeper
Zitieren
APA
Olsson, K. M., Fuge, J., Park, D. H., Kamp, J. C., & Hoeper, M. M. (2025). Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension. European Respiratory Journal, 65(6), 2500064. https://doi.org/10.1183/13993003.00064-2025
Vancouver
Olsson KM, Fuge J, Park DH, Kamp JC, Hoeper MM. Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension. European Respiratory Journal. 2025;65(6):2500064. doi:10.1183/13993003.00064-2025
BibTeX
@article{Olsson2025,
author = {Olsson, Karen M and Fuge, Jan and Park, Da-Hee and Kamp, Jan C and Hoeper, Marius M},
title = {Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension},
journal = {European Respiratory Journal},
year = {2025},
volume = {65},
number = {6},
pages = {2500064},
doi = {10.1183/13993003.00064-2025}
}
EUVIMED